Mesenchymal stem cell therapy for acute respiratory distress syndrome: from basic to clinics

Abstract

The 2019 novel coronavirus disease (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has occurred in China and around the world. SARS-CoV-2-infected patients with severe pneumonia rapidly develop acute respiratory distress syndrome (ARDS) and die of multiple organ failure. Despite advances in supportive care approaches, ARDS is still associated with high mortality and morbidity. Mesenchymal stem cell (MSC)-based therapy may be an potential alternative strategy for treating ARDS by targeting the various pathophysiological events of ARDS. By releasing a variety of paracrine factors and extracellular vesicles, MSC can exert anti-inflammatory, antiapoptotic, anti-microbial, and pro-angiogenic effects, promote bacterial and alveolar fluid clearance, disrupt the pulmonary endothelial and epithelial cell damage, eventually avoiding the lung and distal organ injuries to rescue patients with ARDS. An increasing number of experimental animal studies and early clinical studies verify the safety and efficacy of MSC therapy in ARDS. Since low cell engraftment and survival in lung limit MSC therapeutic potentials, several strategies have been developed to enhance their engraftment in the lung and their intrinsic, therapeutic properties. Here, we provide a comprehensive review of the mechanisms and optimization of MSC therapy in ARDS and highlighted the potentials and possible barriers of MSC therapy for COVID-19 patients with ARDS.

Keywords

mesenchymal stem cells / cell therapy / acute respiratory distress syndrome / SARS-CoV-2 / COVID-19 / pneumonia

References

[1] Abraham A, Krasnodembskaya A (2020) Mesenchymal stem cellderived extracellular vesicles for the treatment of acute respiratory distress syndrome. Stem Cells Transl Med 9:28–38

[2] Alcayaga-Miranda F, Cuenca J, Martin A, Contreras L, Figueroa FE, Khoury M (2015) Combination therapy of menstrual derived mesenchymal stem cells and antibiotics ameliorates survival in sepsis. Stem Cell Res Ther 6:199

[3] Antebi B, Mohammadipoor A, Batchinsky AI, Cancio LC (2018) The promise of mesenchymal stem cell therapy for acute respiratory distress syndrome. J Trauma Acute Care Surg 84:183–191

[4] Atluri S, Manchikanti L, Hirsch JA (2020) Expanded Umbilical Cord Mesenchymal Stem Cells (UC-MSCs) as a therapeutic strategy in managing critically ill COVID-19 patients: the case for compassionate use. Pain Physician 23:E71–E83

[5] Bellani G, Laffey JG, Pham T, Fan E, Brochard L, Esteban A, Gattinoni L, van Haren F, Larsson A, McAuley DF (2016) Epidemiology, patterns of care, and mortality for patients with acute respiratory distress syndrome in intensive care units in 50 countries. JAMA 315:788–800

[6] Bernard O, Jeny F, Uzunhan Y, Dondi E, Terfous R, Label R, Sutton A, Larghero J, Vanneaux V, Nunes H (2018) Mesenchymal stem cells reduce hypoxia-induced apoptosis in alveolar epithelial cells by modulating HIF and ROS hypoxic signaling. Am J Physiol Lung Cell Mol Physiol 314:L360–L371

[7] Bing L, Jun-hui C, Tao L, Hai-ying W, Wen-jie Y, Yan-jiao L, Jianchun L, Cong-tao Y, Fang-ang N, Zhao-xia M (2020) Clinical remission of a critically ill COVID-19 patient treated by human umbilical cord mesenchymal stem cells. ChinaXiv 02.00084v1

[8] Bustos ML, Huleihel L, Meyer EM, Donnenberg AD, Donnenberg VS, Sciurba JD, Mroz L, McVerry BJ, Ellis BM, Kaminski N (2013) Activation of human mesenchymal stem cells impacts their therapeutic abilities in lung injury by increasing interleukin (IL)-10 and IL-1RN levels. Stem Cells Transl Med 2:884–895

[9] Cai S-x, Liu A-r, Chen S, He H-l, Chen Q-h, Xu J-Y, Pan C, Yang Y, Guo F-M, Huang Y-z (2015) Activation of Wnt/β-catenin signalling promotes mesenchymal stem cells to repair injured alveolar epithelium induced by lipopolysaccharide in mice. Stem Cell Res Ther 6:65

[10] Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, Ruan L, Song B, Cai Y, Wei M (2020) A trial of Lopinavir-Ritonavir in adults hospitalized with severe Covid-19. N Engl J Med.https://doi.org/10.1056/NEJMoa2001282

[11] Chacko SM, Ahmed S, Selvendiran K, Kuppusamy ML, Khan M, Kuppusamy P (2010) Hypoxic preconditioning induces the expression of prosurvival and proangiogenic markers in mesenchymal stem cells. Am J Physiol Cell Physiol 299:C1562–C1570

[12] Chan MCW, Kuok DIT, Leung CYH, Hui KPY, Valkenburg SA, Lau EHY, Nicholls JM, Fang X, Guan Y, Lee JW (2016) Human mesenchymal stromal cells reduce influenza A H5N1-associated acute lung injury in vitro and in vivo. Proc Natl Acad Sci USA 113:3621–3626

[13] Chan JF-W, Yuan S, Kok K-H, To KK-W, Chu H, Yang J, Xing F, Liu J, Yip CC-Y, Poon RW-S (2020) A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. The Lancet.https://doi.org/10.1016/S0140-6736(20)30154-9

[14] Chen J, Li C, Gao X, Li C, Liang Z, Yu L, Li Y, Xiao X, Chen L (2013) Keratinocyte growth factor gene delivery via mesenchymal stem cells protects against lipopolysaccharide-induced acute lung injury in mice. PLoS ONE 8:e83303

[15] Chen J, Li Y, Hao H, Li C, Du Y, Hu Y, Li J, Liang Z, Li C, Liu J (2015) Mesenchymal stem cell conditioned medium promotes proliferation and migration of alveolar epithelial cells under septic conditions in vitro via the JNK-P38 signaling pathway. Cell Physiol Biochem 37:1830–1846

[16] Chen S, Chen X, Wu X, Wei S, Han W, Lin J, Kang M, Chen L (2017a) Hepatocyte growth factor-modified mesenchymal stem cells improve ischemia/reperfusion-induced acute lung injury in rats. Gene Ther 24:3–11

[17] Chen H-X, Xiang H, Xu W-H, Li M, Yuan J, Liu J, Sun W-J, Zhang R, Li J, Ren Z-Q (2017b) Manganese superoxide dismutase gene-modified mesenchymal stem cells attenuate acute radiation-induced lung injury. Hum Gene Ther 28:523–532

[18] Chen X, Zhang Y, Wang W, Liu Z, Meng J, Han Z (2018) Mesenchymal stem cells modified with heme oxygenase-1 have enhanced paracrine function and attenuate lipopolysaccharideinduced inflammatory and oxidative damage in pulmonary microvascular endothelial cells. Cell Physiol Biochem 49:101–122

[19] Chen X-X, Tang L, Han Z-H, Wang W-J, Meng J-G (2019a) Coculture with bone marrow-derived mesenchymal stem cells attenuates inflammation and apoptosis in lipopolysaccharidestimulated alveolar epithelial cells via enhanced secretion of keratinocyte growth factor and angiopoietin-1 modulating the Tolllike receptor-4 signal pathway. Mol Med Rep 19:1891–1902

[20] Chen X, Wu S, Tang L, Ma L, Wang F, Feng H, Meng J, Han Z (2019b) Mesenchymal stem cells overexpressing heme oxygenase-1 ameliorate lipopolysaccharide-induced acute lung injury in rats. J Cell Physiol 234:7301–7319

[21] Chen H, Guo J, Wang C, Luo F, Yu X, Zhang W, Li J, Zhao D, Xu D, Gong Q (2020a) Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records. The Lancet 395:809–815

[22] Chen T, Di Wu, Chen H, Yan W, Yang D, Chen G, Ma K, Xu D, Yu H, Wang H (2020b) Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ 368:m1091

[23] Chen J, Hu C, Chen L, Tang L, Zhu Y, Xu X, Chen L, Gao H, Lu X, Yu L (2020c) Clinical study of mesenchymal stem cell treating acute respiratory distress syndrome induced by epidemic Influenza A (H7N9) infection, a hint for COVID-19 treatment. Engineering (Beijing).https://doi.org/10.1016/j.eng.2020.02.006

[24] Chinazzi M, Davis JT, Ajelli M, Gioannini C, Litvinova M, Merler S, Pastore Y, Piontti A, Mu K, Rossi L (2020) The effect of travel restrictions on the spread of the 2019 novel coronavirus (COVID-19) outbreak. Science. https://doi.org/10.1126/science.aba9757

[25] Devaney J, Horie S, Masterson C, Elliman S, Barry F, O’Brien T, Curley GF, O’Toole D, Laffey JG (2015) Human mesenchymal stromal cells decrease the severity of acute lung injury induced by E. coli in the rat. Thorax 70:625–635

[26] Fang X, Neyrinck AP, Matthay MA, Lee JW (2010) Allogeneic human mesenchymal stem cells restore epithelial protein permeability in cultured human alveolar type II cells by secretion of angiopoietin-1. J Biol Chem 285:26211–26222

[27] Fischer UM, Harting MT, Jimenez F, Monzon-Posadas WO, Xue H, Savitz SI, Laine GA, Cox CS (2009) Pulmonary passage is a major obstacle for intravenous stem cell delivery: the pulmonary first-pass effect. Stem Cells Dev 18:683–692

[28] Garcia-Olmo D, Schwartz DA (2015) Cumulative evidence that mesenchymal stem cells promote healing of perianal fistulas of patients with Crohn’s disease-going from bench to bedside. Gastroenterology 149:853–857

[29] Ghinai I, McPherson TD, Hunter JC, Kirking HL, Christiansen D, Joshi K, Rubin R, Morales-Estrada S, Black SR, Pacilli M (2020) First known person-to-person transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the USA. The Lancet.https://doi.org/10.1016/S0140-6736(20)30607-3

[30] Golpanian S, Wolf A, Hatzistergos KE, Hare JM (2016) Rebuilding the damaged heart: mesenchymal stem cells, cell-based therapy, and engineered heart tissue. Physiol Rev 96:1127–1168

[31] Goolaerts A, Pellan-Randrianarison N, Larghero J, Vanneaux V, Uzunhan Y, Gille T, Dard N, Plan�s C, Matthay MA, Clerici C (2014) Conditioned media from mesenchymal stromal cells restore sodium transport and preserve epithelial permeability in an in vitro model of acute alveolar injury. Am J Physiol Lung Cell Mol Physiol 306:L975–L985

[32] Goyal P, Choi JJ, Pinheiro LC, Schenck EJ, Chen R, Jabri A, Satlin MJ, Campion TR, Nahid M, Ringel JB (2020) Clinical characteristics of Covid-19 in New York City. N Engl J Med.https://doi.org/10.1056/NEJMc2010419

[33] Guan W-J, Ni Z-Y, Hu Y, Liang W-H, Ou C-Q, He J-X, Liu L, Shan H, Lei C-L, Hui DSC (2020) Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med.https://doi.org/10.1056/NEJMoa2002032

[34] G�ldner A, Maron-Gutierrez T, Abreu SC, Xisto DG, Senegaglia AC, Barcelos PRdS, Silva JD, Brofman P, de Abreu MG, Rocco PRM (2015) Expanded endothelial progenitor cells mitigate lung injury in septic mice. Stem Cell Res Ther 6:230

[35] Gupta N, Krasnodembskaya A, Kapetanaki M, Mouded M, Tan X, Serikov V, Matthay MA (2012) Mesenchymal stem cells enhance survival and bacterial clearance in murine Escherichia coli pneumonia. Thorax 67:533–539

[36] Haberman R, Axelrad J, Chen A, Castillo R, Yan Di, Izmirly P, Neimann A, Adhikari S, Hudesman D, Scher JU (2020) Covid-19 in immune-mediated inflammatory diseases—case series from New York. N Engl J Med. https://doi.org/10.1056/NEJMc2009567

[37] Han J, Li Y, Li Y (2019) Strategies to enhance mesenchymal stem cell-based therapies for acute respiratory distress syndrome. Stem Cells Int 2019:5432134

[38] Hao Q, Zhu Y-g, Monsel A, Gennai S, Lee T, Xu F, Lee J-W (2015) Study of bone marrow and embryonic stem cell-derived human mesenchymal stem cells for treatment of escherichia coli endotoxin-induced acute lung injury in mice. Stem Cells Transl Med 4:832–840

[39] Hao Q, Gudapati V, Monsel A, Park JH, Hu S, Kato H, Lee JH, Zhou L, He H, Lee JW (2019) Mesenchymal stem cell-derived extracellular vesicles decrease lung injury in mice. J Immunol 203:1961–1972

[40] He H-l, Liu L, Chen Q-h, Cai S-x, Han J-B, Hu S-L, Chun P, Yang Y, Guo F-M, Huang Y-z (2015) MSCs modified with ACE2 restore endothelial function following LPS challenge by inhibiting the activation of RAS. J Cell Physiol 230:691–701

[41] Holshue ML, DeBolt C, Lindquist S, Lofy KH, Wiesman J, Bruce H, Spitters C, Ericson K, Wilkerson S, Tural A (2020) First case of 2019 novel coronavirus in the United States. N Engl J Med.https://doi.org/10.1056/NEJMoa2001191

[42] Hu S, Li J, Xu X, Liu A, He H, Xu J, Chen Q, Liu S, Liu L, Qiu H (2016) The hepatocyte growth factor-expressing character is required for mesenchymal stem cells to protect the lung injured by lipopolysaccharide in vivo. Stem Cell Res Ther 7:66

[43] Hu S, Park J, Liu A, Lee J, Zhang X, Hao Q, Lee J-W (2018) Mesenchymal stem cell microvesicles restore protein permeability across primary cultures of injured human lung microvascular endothelial cells. Stem Cells Transl Med 7:615–624

[44] Huang Z, Liu H, Zhang X, Wen G, Zhu C, Zhao Y, Niu W, Qin Y, Chen H, Bai C (2018) Transcriptomic analysis of lung tissues after hUC-MSCs and FTY720 treatment of lipopolysaccharideinduced acute lung injury in mouse models. Int Immunopharmacol 63:26–34

[45] Ionescu L, Byrne RN, van Haaften T, Vadivel A, Alphonse RS, Rey-Parra GJ, Weissmann G, Hall A, Eaton F, Th�baud B (2012) Stem cell conditioned medium improves acute lung injury in mice: in vivo evidence for stem cell paracrine action. Am J Physiol Lung Cell Mol Physiol 303:L967–L977

[46] Islam D, Huang Y, Fanelli V, Delsedime L, Wu S, Khang J, Han B, Grassi A, Li M, Xu Y (2019) Identification and modulation of microenvironment is crucial for effective mesenchymal stromal cell therapy in acute lung injury. Am J Respir Crit Care Med 199:1214–1224

[47] Jackson MV, Morrison TJ, Doherty DF, McAuley DF, Matthay MA, Kissenpfennig A, O’Kane CM, Krasnodembskaya AD (2016) Mitochondrial transfer via tunneling nanotubes is an important mechanism by which mesenchymal stem cells enhance macrophage phagocytosis in the in vitro and in vivo models of ARDS. Stem Cells 34:2210–2223

[48] Kandel N, Chungong S, Omaar A, Xing J (2020) Health security capacities in the context of COVID-19 outbreak: an analysis of International Health Regulations annual report data from 182 countries. The Lancet.https://doi.org/10.1016/S0140-6736(20) 30553-5

[49] Kim ES, Chang YS, Choi SJ, Kim JK, Yoo HS, Ahn SY, Sung DK, Kim SY, Park YR, Park WS (2011) Intratracheal transplantation of human umbilical cord blood-derived mesenchymal stem cells attenuates Escherichia coli-induced acute lung injury in mice. Respir Res 12:108

[50] Koff WC, Williams MA (2020) Covid-19 and immunity in aging populations—a new research agenda. N Engl J Med.https://doi.org/10.1056/NEJMp2006761

[51] Krasnodembskaya A, Song Y, Fang X, Gupta N, Serikov V, Lee J-W, Matthay MA (2010) antibacterial effect of human mesenchymal stem cells is mediated in part from secretion of the antimicrobial peptide LL-37. Stem Cells 28:2229–2238

[52] Krasnodembskaya A, Samarani G, Song Y, Zhuo H, Su X, Lee J-W, Gupta N, Petrini M, Matthay MA (2012) Human mesenchymal stem cells reduce mortality and bacteremia in gram-negative sepsis in mice in part by enhancing the phagocytic activity of blood monocytes. Am J Physiol Lung Cell Mol Physiol 302: L1003–L1013

[53] Kucharski AJ, Russell TW, Diamond C, Liu Y, Edmunds J, Funk S, Eggo RM, Sun F, Jit M, Munday JD (2020) Early dynamics of transmission and control of COVID-19: a mathematical modelling study. Lancet Infect Dis.https://doi.org/10.1016/S1473-3099(20) 30144-4

[54] Laffey JG, Matthay MA (2017) Fifty years of research in ARDS. Cellbased therapy for acute respiratory distress syndrome. biology and potential therapeutic value. Am J Respir Crit Care Med 196:266–273

[55] Lan Y-W, Choo K-B, Chen C-M, Hung T-H, Chen Y-B, Hsieh C-H, Kuo H-P, Chong K-Y (2015) Hypoxia-preconditioned mesenchymal stem cells attenuate bleomycin-induced pulmonary fibrosis. Stem Cell Res Ther 6:97

[56] Lan J, Ge J, Yu J, Shan S, Zhou H, Fan S, Zhang Q, Shi X, Wang Q, Zhang L, Wang X (2020) Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature.https://doi.org/10.1038/s41586-020-2180-5

[57] Le HT, Nguyen LV, Tran DM, Do HT, Tran HT, Le YT, Phan PH (2020) The first infant case of COVID-19 acquired from a secondary transmission in Vietnam. Lancet Child Adolesc Health.https://doi.org/10.1016/S2352-4642(20)30091-2

[58] Le Blanc K, Mougiakakos D (2012) Multipotent mesenchymal stromal cells and the innate immune system. Nat Rev Immunol 12:383–396

[59] Lee C-W, Chen Y-F, Wu H-H, Lee OK (2018) Historical perspectives and advances in mesenchymal stem cell research for the treatment of liver diseases. Gastroenterology 154:46–56

[60] Lee JH, Park J, Lee J-W (2019) Therapeutic use of mesenchymal stem cell-derived extracellular vesicles in acute lung injury. Transfusion 59:876–883

[61] Lee RH, Pulin AA, Seo MJ, Kota DJ, Ylostalo J, Larson BL, Semprun-Prieto L, Delafontaine P, Prockop DJ (2009) Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the antiinflammatory protein TSG-6. Cell Stem Cell 5:54–63

[62] Lee JW, Krasnodembskaya A, McKenna DH, Song Y, Abbott J, Matthay MA (2013) Therapeutic effects of human mesenchymal stem cells in ex vivo human lungs injured with live bacteria. Am J Respir Crit Care Med 187:751–760

[63] Leng Z, Zhu R, Hou W, Feng Y, Yang Y, Han Q, Shan G, Meng F, Du D, Wang S (2020) Transplantation of ACE2-mesenchymal stem cells improves the outcome of patients with COVID-19 pneumonia. Aging Dis 11:216–228

[64] Li B, Zhang H, Zeng M, He W, Li M, Huang X, Deng DYB, Wu J (2015) Bone marrow mesenchymal stem cells protect alveolar macrophages from lipopolysaccharide-induced apoptosis partially by inhibiting the Wnt/β-catenin pathway. Cell Biol Int 39:192–200

[65] Li D, Liu Q, Qi L, Dai X, Liu H, Wang Y (2016) Low levels of TGF-β1 enhance human umbilical cord-derived mesenchymal stem cell fibronectin production and extend survival time in a rat model of lipopolysaccharide-induced acute lung injury. Mol Med Rep 14:1681–1692

[66] Li Y, Shi X, Yang L, Mou Y, Li Y, Dang R, Li C (2017) Hypoxia promotes the skewed differentiation of umbilical cord mesenchymal stem cells toward type II alveolar epithelial cells by regulating microRNA-145. Gene 630:68–75

[67] Li M-Y, Li L, Zhang Y, Wang X-S (2020) Expression of the SARSCoV-2 cell receptor gene ACE2 in a wide variety of human tissues. Infect Dis Poverty 9:45

[68] Liao M, Liu Y, Yuan J, Wen Y, Xu G, Zhao J, Chen L, Li J, Wang X, Wang F (2020) The landscape of lung bronchoalveolar immune cells in COVID-19 revealed by single-cell RNA sequencing

[69] Liu A-r, Liu Le, Chen S, Yang Y, Zhao H-J, Liu L, Guo F-M, Lu X-M, Qiu H-B (2013) Activation of canonical wnt pathway promotes differentiation of mouse bone marrow-derived MSCs into type II alveolar epithelial cells, confers resistance to oxidative stress, and promotes their migration to injured lung tissue in vitro. J Cell Physiol 228:1270–1283

[70] Lopes-Pacheco M, Robba C, Rocco PRM, Pelosi P (2019) Current understanding of the therapeutic benefits of mesenchymal stem cells in acute respiratory distress syndrome. Cell Biol Toxicol.https://doi.org/10.1007/s10565-019-09493-5

[71] Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, Wang W, Song H, Huang B, Zhu N (2020) Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. The Lancet.https://doi.org/10.1016/S0140-6736(20)30251-8

[72] Maron-Gutierrez T, Silva JD, Asensi KD, Bakker-Abreu I, Shan Y, Diaz BL, Goldenberg RCS, Mei SHJ, Stewart DJ, Morales MM (2013) Effects of mesenchymal stem cell therapy on the time course of pulmonary remodeling depend on the etiology of lung injury in mice. Crit Care Med 41:e319–e333

[73] Mart�nez-Gonz�lez I, Roca O, Masclans JR, Moreno R, Salcedo MT, Baekelandt V, Cruz MJ, Rello J, Aran JM (2013) Human mesenchymal stem cells overexpressing the IL-33 antagonist soluble IL-1 receptor-like-1 attenuate endotoxin-induced acute lung injury. Am J Respir Cell Mol Biol 49:552–562

[74] Matthay MA, Calfee CS, Zhuo H, Thompson BT, Wilson JG, Levitt JE, Rogers AJ, Gotts JE, Wiener-Kronish JP, Bajwa EK (2019) Treatment with allogeneic mesenchymal stromal cells for moderate to severe acute respiratory distress syndrome (START study): a randomised phase 2a safety trial. Lancet Respir Med 7:154–162

[75] McIntyre LA, Moher D, Fergusson DA, Sullivan KJ, Mei SHJ, Lalu M, Marshall J, Mcleod M, Griffin G, Grimshaw J (2016) Efficacy of mesenchymal stromal cell therapy for acute lung injury in preclinical animal models: a systematic review. PLoS ONE 11: e0147170

[76] Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ (2020) COVID-19: consider cytokine storm syndromes and immunosuppression. The Lancet 395:1033–1034

[77] Mei SHJ, McCarter SD, Deng Y, Parker CH, Liles WC, Stewart DJ (2007) Prevention of LPS-induced acute lung injury in mice by mesenchymal stem cells overexpressing angiopoietin 1. PLoS Med 4:e269

[78] Meng S-S, Guo F-M, Zhang X-W, Chang W, Peng F, Qiu H-B, Yang Y (2019) mTOR/STAT-3 pathway mediates mesenchymal stem cell-secreted hepatocyte growth factor protective effects against lipopolysaccharide-induced vascular endothelial barrier dysfunction and apoptosis. J Cell Biochem 120:3637–3650

[79] Millar JE, von Bahr V, Malfertheiner MV, Ki KK, Redd MA, Bartnikowski N, Suen JY, McAuley DF, Fraser JF (2019) Administration of mesenchymal stem cells during ECMO results in a rapid decline in oxygenator performance. Thorax 74:194–196

[80] Mokhber Dezfouli MR, Jabbari Fakhr M, Sadeghian Chaleshtori S, Dehghan MM, Vajhi A, Mokhtari R (2018) Intrapulmonary autologous transplant of bone marrow-derived mesenchymal stromal cells improves lipopolysaccharide-induced acute respiratory distress syndrome in rabbit. Crit Care 22:353

[81] Molendijk I, Bonsing BA, Roelofs H, Peeters KCMJ, Wasser MNJM, Dijkstra G, van der Woude CJ, Duijvestein M, Veenendaal RA, Zwaginga J-J (2015) Allogeneic bone marrow-derived mesenchymal stromal cells promote healing of refractory perianal fistulas in patients with Crohn’s disease. Gastroenterology 149:918-27.e6

[82] Monteil V, Kwon H, Prado P, Hagelkr�ys A, Wimmer RA, Stahl M, Leopoldi A, Garreta E, Hurtado Del Pozo C, Prosper F (2020) Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2. Cell.https://doi.org/10.1016/j.cell.2020.04.004

[83] Papazian L, Aubron C, Brochard L, Chiche J-D, Combes A, Dreyfuss D, Forel J-M, Gu�rin C, Jaber S, Mekontso-Dessap A (2019) Formal guidelines: management of acute respiratory distress syndrome. Ann Intensiv Care 9:69

[84] Park J, Kim S, Lim H, Liu A, Hu S, Lee J, Zhuo H, Hao Q, Matthay MA, Lee J-W (2019) Therapeutic effects of human mesenchymal stem cell microvesicles in an ex vivo perfused human lung injured with severe E. coli pneumonia. Thorax 74:43–50

[85] Pedrazza L, Cunha AA, Luft C, Nunes NK, Schimitz F, Gassen RB, Breda RV, Donadio MVF, Souza Wyse AT, Pitrez PMC (2017) Mesenchymal stem cells improves survival in LPSinduced acute lung injury acting through inhibition of NETs formation. J Cell Physiol 232:3552–3564

[86] Perico L, Morigi M, Rota C, Breno M, Mele C, Noris M, Introna M, Capelli C, Longaretti L, Rottoli D (2017) Human mesenchymal stromal cells transplanted into mice stimulate renal tubular cells and enhance mitochondrial function. Nat Commun 8:983

[87] Qin Z-h, Xu J-f, Qu J-M, Zhang J, Sai Y, Chen C-m, Wu L, Yu L (2012) Intrapleural delivery of MSCs attenuates acute lung injury by paracrine/endocrine mechanism. J Cell Mol Med 16:2745–2753

[88] Ranieri VM, Rubenfeld GD, Thompson BT, Ferguson ND, Caldwell E, Fan E, Camporota L, Slutsky AS (2012) Acute respiratorydistress syndrome: the Berlin Definition. JAMA 307:2526–2533

[89] Ren H, Zhang Q, Wang J, Pan R (2018) Comparative effects ofumbilical cord- and menstrual blood-derived MSCs in repairing acute lung injury. Stem Cells Int 2018:7873625

[90] Ronco C, Reis T (2020) Kidney involvement in COVID-19 and rationale for extracorporeal therapies. Nat Rev Nephrol.https://doi.org/10.1038/s41581-020-0284-7

[91] Schett G, Sticherling M, Neurath MF (2020) COVID-19: risk for cytokine targeting in chronic inflammatory diseases? Nat Rev Immunol 20:271–272

[92] Shang J, Ye G, Shi K, Wan Y, Luo C, Aihara H, Geng Q, Auerbach A, Li F (2020) Structural basis of receptor recognition by SARSCoV-2. Nature.https://doi.org/10.1038/s41586-020-2179-y

[93] Shao Y, Shen J, Zhou F, He D (2018) Mesenchymal stem cells overexpressing Ang1 attenuates phosgene-induced acute lung injury in rats. Inhal Toxicol 30:313–320

[94] Shao Y, Zhou F, He D, Zhang L, Shen J (2019) Overexpression of CXCR7 promotes mesenchymal stem cells to repair phosgeneinduced acute lung injury in rats. Biomed Pharmacother 109:1233–1239

[95] Silva JD, Lopes-Pacheco M, Paz AHR, Cruz FF, Melo EB, de Oliveira MV, Xisto DG, Capelozzi VL, Morales MM, Pelosi P (2018) Mesenchymal stem cells from bone marrow, adipose tissue, and lung tissue differentially mitigate lung and distal organ damage in experimental acute respiratory distress syndrome. Crit Care Med 46:e132–e140

[96] Simonson OE, Mougiakakos D, Heldring N, Bassi G, Johansson HJ, Dal�n M, Jitschin R, Rodin S, Corbascio M, El Andaloussi S (2015) In vivo effects of mesenchymal stromal cells in two patients with severe acute respiratory distress syndrome. Stem Cells Transl Med 4:1199–1213

[97] Stappenbeck TS, Miyoshi H (2009) The role of stromal stem cells in tissue regeneration and wound repair. Science 324:1666–1669

[98] Stebbing J, Phelan A, Griffin I, Tucker C, Oechsle O, Smith D, Richardson P (2020) COVID-19: combining antiviral and antiinflammatory treatments. Lancet Infect Dis 20:400–402

[99] Su VY-F, Lin C-S, Hung S-C, Yang K-Y (2019) Mesenchymal stem cell-conditioned medium induces neutrophil apoptosis associated with inhibition of the NF-κB pathway in endotoxin-induced acute lung injury. Int J Mol Sci.https://doi.org/10.3390/ijms20092208

[100] Sun K, Chen J, Viboud C (2020) Early epidemiological analysis of the coronavirus disease 2019 outbreak based on crowdsourced data: a population-level observational study. Lancet Digit Health 2:e201–e208

[101] Sung DK, Chang YS, Sung S, Yoo HS, Ahn SY, Park WS (2016) Antibacterial effect of mesenchymal stem cells against Escherichia coli is mediated by secretion of beta- defensin- 2 via toll- like receptor 4 signalling. Cell Microbiol 18:424–436

[102] van de Veerdonk FL, Netea MG, van Deuren M, van der Meer JW, de Mast Q, Br�ggemann RJ, van der Hoeven H (2020) Kallikreinkinin blockade in patients with COVID-19 to prevent acute respiratory distress syndrome. Elife.https://doi.org/10.7554/eLife.57555

[103] Vaninov N (2020) In the eye of the COVID-19 cytokine storm. Nat Rev Immunol 20:277

[104] Varga Z, Flammer AJ, Steiger P, Haberecker M, Andermatt R, Zinkernagel AS, Mehra MR, Schuepbach RA, Ruschitzka F, Moch H (2020) Endothelial cell infection and endotheliitis in COVID-19. The Lancet 395:1417–1418

[105] Walls AC, Park Y-J, Tortorici MA, Wall A, McGuire AT, Veesler D (2020) Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell 181:281–292.e6

[106] Wang Y-Y, Li X-Z, Wang L-B (2013) Therapeutic implications of mesenchymal stem cells in acute lung injury/acute respiratory distress syndrome. Stem Cell Res Ther 4:45

[107] Wang L, Shi M, Tong L, Wang J, Ji S, Bi J, Chen C, Jiang J, Bai C, Zhou J (2019) Lung-resident mesenchymal stem cells promote repair of LPS-induced acute lung injury via regulating the balance of regulatory T cells and Th17 cells. Inflammation 42:199–210

[108] Wang L, He W, Yu X, Hu D, Bao M, Liu H, Zhou J, Jiang H (2020a) Coronavirus disease 2019 in elderly patients: characteristics and prognostic factors based on 4-week follow-up. J Infect.https://doi.org/10.1016/j.jinf.2020.03.019

[109] Wang Q, Zhang Y, Wu L, Niu S, Song C, Zhang Z, Lu G, Qiao C, Hu Y, Yuen K-Y (2020b) Structural and functional basis of SARS-CoV-2 entry by using human ACE2. Cell.https://doi.org/10.1016/j.cell.2020.03.045

[110] Wilson JG, Liu KD, Zhuo H, Caballero L, McMillan M, Fang X, Cosgrove K, Vojnik R, Calfee CS, Lee J-W (2015) Mesenchymal stem (stromal) cells for treatment of ARDS: a phase 1 clinical trial. Lancet Respir Med 3:24–32

[111] Xiang B, Chen L, Wang X, Zhao Y, Wang Y, Xiang C (2017) Transplantation of menstrual blood-derived mesenchymal stem cells promotes the repair of LPS-induced acute lung injury. Int J Mol Sci.https://doi.org/10.3390/ijms18040689

[112] Xu J, Qu J, Cao L, Sai Y, Chen C, He L, Yu L (2008) Mesenchymal stem cell-based angiopoietin-1 gene therapy for acute lung injury induced by lipopolysaccharide in mice. J Pathol 214:472–481

[113] Xu X-P, Huang L-L, Hu S-L, Han J-B, He H-l, Xu J-Y, Xie J-F, Liu A-r, Liu S-Q, Liu L (2018) Genetic modification of mesenchymal stem cells overexpressing angiotensin II Type 2 receptor increases cell migration to injured lung in LPS-induced acute lung injury mice. Stem Cells Transl Med 7:721–730

[114] Xu N, Shao Y, Ye K, Qu Y, Memet O, He D, Shen J (2019) Mesenchymal stem cell-derived exosomes attenuate phosgeneinduced acute lung injury in rats. Inhal Toxicol 31:52–60

[115] Xu Y, Li X, Zhu B, Liang H, Fang C, Gong Y, Guo Q, Sun X, Zhao D, Shen J (2020a) Characteristics of pediatric SARS-CoV-2 infection and potential evidence for persistent fecal viral shedding. Nat Med 395:470

[116] Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, Liu S, Zhao P, Liu H, Zhu L (2020b) Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med 8:420–422

[117] Yan X, Fu X, Jia Y, Ma X, Tao J, Yang T, Ma H, Liang X, Liu X, Yang J (2019) Nrf2/Keap1/ARE signaling mediated an antioxidative protection of human placental mesenchymal stem cells of fetal origin in alveolar epithelial cells. Oxid Med Cell Longev 2019:2654910

[118] Yan R, Zhang Y, Li Y, Xia L, Guo Y, Zhou Q (2020) Structural basis for the recognition of the SARS-CoV-2 by full-length human ACE2. Science.https://doi.org/10.1126/science.abb2762

[119] Yang J-X, Zhang N, Wang H-W, Gao P, Yang Q-P, Wen Q-P (2015a) CXCR4 receptor overexpression in mesenchymal stem cells facilitates treatment of acute lung injury in rats. J Biol Chem 290:1994–2006

[120] Yang Y, Chen Q-h, Liu A-r, Xu X-P, Han J-B, Qiu H-B (2015b) Synergism of MSC-secreted HGF and VEGF in stabilising endothelial barrier function upon lipopolysaccharide stimulation via the Rac1 pathway. Stem Cell Res Ther 6:250

[121] Yang Y, Shen C, Li J, Yuan J, Wei J, Huang F, Wang F, Li G, Li Y, Xing L (2020) Plasma IP-10 and MCP-3 levels are highly associated with disease severity and predict the progression of COVID-19. J Allergy Clin Immunol.https://doi.org/10.1016/j.jaci.2020.04.027

[122] Yuan M, Wu NC, Zhu X, Lee C-CD, So RTY, Lv H, Mok CKP, Wilson IA (2020) A highly conserved cryptic epitope in the receptorbinding domains of SARS-CoV-2 and SARS-CoV. Science

[123] Zhang W, Liu L, Huo Y, Yang Y, Wang Y (2014) Hypoxia-pretreated human MSCs attenuate acute kidney injury through enhanced angiogenic and antioxidative capacities. Biomed Res Int 2014:462472

[124] Zhang C, Zhu Y, Wang J, Hou L, Li W, An H (2019a) CXCR4-overexpressing umbilical cord mesenchymal stem cells enhance protection against radiation-induced lung injury. Stem Cells Int 2019:2457082

[125] Zhang L, Li Q, Liu W, Liu Z, Shen H, Zhao M (2019b) Mesenchymal stem cells alleviate acute lung injury and inflammatory responses induced by paraquat poisoning. Med Sci Monit 25:2623–2632

[126] Zhang X, Chen J, Xue M, Tang Y, Xu J, Liu L, Huang Y, Yang Y, Qiu H, Guo F (2019c) Overexpressing p130/E2F4 in mesenchymal stem cells facilitates the repair of injured alveolar epithelial cells in LPS-induced ARDS mice. Stem Cell Res Ther 10:74

[127] Zhang H, Penninger JM, Li Y, Zhong N, Slutsky AS (2020) Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. Intensiv Care Med 46:586–590

[128] Zhao Y-F, Xiong W, Wu X-L (2014) Mesenchymal stem cell-based developmental endothelial locus-1 gene therapy for acute lung injury induced by lipopolysaccharide in mice. Mol Med Rep 9:1583–1589

[129] Zhao Y, Zhao Z, Wang Y, Zhou Y, Ma Y, Zuo W (2020) Single-cell RNA expression profiling of ACE2, the receptor of SARS-CoV-2

[130] Zheng G, Huang L, Tong H, Shu Q, Hu Y, Ge M, Deng K, Zhang L, Zou B, Cheng B (2014) Treatment of acute respiratory distress syndrome with allogeneic adipose-derived mesenchymal stem cells: a randomized, placebo-controlled pilot study. Respir Res 15:39

[131] Zheng M, Gao Y, Wang G, Song G, Liu S, Sun D, Xu Y, Tian Z (2020) Functional exhaustion of antiviral lymphocytes in COVID-19 patients. Cell Mol Immunol 17:533–535

[132] Zhou Z, You Z (2016) Mesenchymal stem cells alleviate LPSinduced acute lung injury in mice by MiR-142a-5p-controlled pulmonary endothelial cell autophagy. Cell Physiol Biochem 38:258–266

[133] Zhou P, Yang X-L, Wang X-G, Hu B, Zhang L, Zhang W, Si H-R, Zhu Y, Li B, Huang C-L (2020a) A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579:270–273

[134] Zhou Y, Fu B, Zheng X, Wang D, Zhao C, Qi Y, Sun R, Tian Z, Xu X, Wei H (2020b) Pathogenic T cells and inflammatory monocytes incite inflammatory storm in severe COVID-19 patients. Natl Sci Rev.https://doi.org/10.1093/nsr/nwaa041

[135] Zhu H, Xiong Y, Xia Y, Zhang R, Tian D, Wang T, Dai J, Wang L, Yao H, Jiang H (2017) Therapeutic effects of human umbilical cord-derived mesenchymal stem cells in acute lung injury mice. Sci Rep 7:39889

[136] Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, Zhao X, Huang B, Shi W, Lu R (2020) A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med.https://doi.org/10.1056/NEJMoa2001017

RIGHTS & PERMISSIONS

2020 The Author(s) 2020